IMPROVED CRYSTALLINE FORM OF THE COMPOUND A-348441

There is provided a hemihydrate of (3 ,5 ,7α,12α)-7,12-dihydroxy-3-{2-[{4-[17 -hydroxy-3-oxo-17α-prop-1-ynylestra-4,9-dien-11 -yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2 =6.58±0.2, 8.54+0.2, 1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CINK, RUSSELLEW, LONG, MICHELLE, ANDREE, LEANNA, MARVIN, ROBERT, ZOU, DAOZHONG, TOMA, PASCAL, H
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS STEROIDS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	There is provided a hemihydrate of (3 ,5 ,7α,12α)-7,12-dihydroxy-3-{2-[{4-[17 -hydroxy-3-oxo-17α-prop-1-ynylestra-4,9-dien-11 -yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2 =6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response.